Results 61 to 70 of about 1,013 (109)

Brain Penetration of Lorlatinib: Cumulative Incidences of CNS and Non-CNS Progression with Lorlatinib in Patients with Previously Treated ALK-Positive Non-Small-Cell Lung Cancer [PDF]

, 2020
Lorlatinib; Càncer de pulmóLorlatinib; Cáncer de pulmónLorlatinib; Lung CancerBackground Lorlatinib is a potent, third-generation ALK/ROS1 tyrosine kinase inhibitor (TKI) designed to penetrate the blood–brain barrier.
Navarro Mendivil, Alejandro, Thurm, Holger, Felip Font, Enriqueta, Johnson, Melissa L., Gainor, Justin F., Shaw, Alice Tsang, Bauer, Todd   +6 more
core   +1 more source

Concurrent Stereotactic Radiotherapy and Immune Checkpoint Inhibitors for Multiple Brain Metastases in Non‐Small Cell Lung Cancer ‐ A Multi‐Center Retrospective Analysis

CNS Neuroscience &Therapeutics, Volume 32, Issue 8, August 2026.
Initiating ICIs within 14 days post SRT, especially at a short interval after radiotherapy, markedly extends OS and iPFS, with no elevated risks of RN or adverse events. ABSTRACT Background This study aimed to evaluate the efficacy and safety of concurrent versus sequential stereotactic radiotherapy (SRT) and immune checkpoint inhibitors (ICIs) in non ...
Xiaoliang Wang, Yanan Zheng, Aimin Wang, Xiaolan Zhao, Kai Guan, Qiong Huang, Jiali Du   +6 more
wiley   +1 more source

Prediction of ALK mutations mediating ALK-TKIs resistance and drug re-purposing to overcome the resistanceResearch in context

EBioMedicine, 2019
Background: Alectinib has shown a greater efficacy to ALK-rearranged non-small-cell lung cancers in first-line setting; however, most patients relapse due to acquired resistance, such as secondary mutations in ALK including I1171N and G1202R.
Koutaroh Okada, Mitsugu Araki, Takuya Sakashita, Biao Ma, Ryo Kanada, Noriko Yanagitani, Atsushi Horiike, Sumie Koike, Tomoko Oh-hara, Kana Watanabe, Keiichi Tamai, Makoto Maemondo, Makoto Nishio, Takeshi Ishikawa, Yasushi Okuno, Naoya Fujita, Ryohei Katayama   +16 more
doaj   +1 more source

The Role of Precision Medicine in Neuroblastoma: Targeted Therapies and Personalized Approaches—A Narrative Review

Health Science Reports, Volume 9, Issue 8, August 2026.
ABSTRACT Background and Aims Neuroblastoma is the most common extracranial solid tumor and contributes the most to pediatric oncology deaths worldwide. Its clinical manifestations are heterogeneous, including relapses, and the prognosis remains poor, especially for high‐risk patients.
Mosammat Jannatul Mawa, Mohammad Shahangir Biswas, Maksudul Haque, Munna Kumar Podder   +3 more
wiley   +1 more source

Pan‐HER inhibitors overcome lorlatinib resistance caused by NRG1/HER3 activation in ALK‐rearranged lung cancer [PDF]

Lorlatinib, a third‐generation anaplastic lymphoma kinase (ALK)‐tyrosine kinase inhibitor (TKI) with a broad coverage against ALK mutations, has demonstrated dramatic effects in patients with ALK‐rearranged lung cancer.
Taniguchi, Hirokazu, Gyotoku, Hiroshi, Mukae, Hiroshi, Yamada, Tadaaki, Ono, Sawana, Dotsu, Yosuke, Yamaguchi, Hiroyuki, Yano, Seiji, Sen, Triparna, Imamura, Erika, Akagi, Kazumasa, Takemoto, Shinnosuke   +11 more
core   +2 more sources

Efficacy and safety analysis of lorlatinib for ALK-positive advanced NSCLC: a multicentre real-world study in China

BMC Cancer
Background Lorlatinib, a third-generation Anaplastic lymphoma kinase (ALK)-tyrosine kinase inhibitors (TKI), has demonstrated excellent curative effect in clinical studies to overcome mutations resistant to first- and second-generation ALK-TKIs.
Zhujun Chen, Chunlan Tang, Xiangyu Ma, Panwen Tian, Liang Gong   +4 more
doaj   +1 more source

Lung Cancer in Never Smokers—An Underappreciated Public Health Burden

Health Science Reports, Volume 9, Issue 8, August 2026.
ABSTRACT Background Lung cancer in lifelong never‐smokers represents a significant public health burden, although it is underappreciated. Lung cancer in never smokers (LCINS) accounts for a substantial proportion of lung cancer cases, representing ~15%–25% depending on the geographic region.
Md Mohiuddin
wiley   +1 more source

Long-Term Efficacy and Safety of Lorlatinib in Japanese Patients With ALK-Positive Advanced NSCLC—A Brief Report From the CROWN Study

JTO Clinical and Research Reports
Introduction: Lorlatinib was found to have improved efficacy versus crizotinib in the global phase 3 CROWN study (NCT03052608). Similar results were revealed for the Japanese population as for the overall population. We present results from the unplanned
Shunsuke Teraoka, MD, Hidetoshi Hayashi, MD, PhD, Yasushi Goto, MD, PhD, Makoto Nishio, MD, PhD, Shunichi Sugawara, MD, PhD, Takao Inoue, MD, Satoshi Oizumi, MD, PhD, Shigeyuki Toyoizumi, MS, Masakazu Matsumura, MS, Rossella Messina, PharmD, PhD, Terufumi Kato, MD   +10 more
doaj   +1 more source

Concurrent Treatment With Lorlatinib and Dinutuximab Beta Induced Acute Gastric Dilation in a Pediatric Patient With Neuroblastoma

Pediatric Blood &Cancer, Volume 73, Issue 10, October 2026.
Suna Lin, Linjie Li, JiJun Chen, Zhaokun Tao, Lifeng Zhang, Junqing Mao, Jinhu Wang   +6 more
wiley   +1 more source

Systemic anti‐cancer therapy associated with the occurrence of peripheral neurotoxicity and, specifically, peripheral neuropathy

International Journal of Cancer, Volume 159, Issue 2, Page 460-466, 15 July 2026.
What's new? While the effectiveness of systemic anticancer therapy is well documented, it commonly causes severe toxicity. This study of the 467 systemic anticancer therapy agents currently approved globally for clinical and/or research purposes found that peripheral neurotoxicity is associated with 45% of classical chemotherapies, 21% of targeted ...
Cassie Higgins, Lynn R. Gauthier, Blair H. Smith, Lesley Colvin   +3 more
wiley   +1 more source